Haemophilia gene therapy trial stopped
A US biotechnology firm announced last week that it is discontinuing its haemophilia trial, citing technical and safety reasons. Avigen said that it was stopping the trial so it could concentrate on neurological diseases, but it also said that the gene therapy treatment for haemophilia faced 'certain scientific, regulatory and...
Comment
The genetic 'trickle effect'
by Dr Jess Buxton
Biology's Apollo landing', 'the outstanding achievement of human history' and the 'language in which God created life': just a few of the comments that accompanied the unveiling of the rough draft of the human genome in June 2000. By April 2003, when the final version was published, the media attention...